Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients

a meta-analysis of randomised controlled trials

Huilin Tang, Xi Zhang, Jingjing Zhang, Yufeng Li, Liana C. Del Gobbo, Suodi Zhai, Yiqing Song

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Aims/hypothesis: By analysing available evidence from randomised controlled trials (RCTs), we aimed to examine whether and to what extent sodium–glucose cotransporter 2 (SGLT2) inhibitors affect serum electrolyte levels in type 2 diabetes patients. Methods: We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov up to 24 May 2016 for published RCTs of SGLT2 inhibitors that reported changes in serum electrolyte levels. Weighted mean differences (WMD) between each SGLT2 inhibitor and placebo were calculated using a random-effects model. Dose-dependent relationships for each SGLT2 inhibitor were evaluated using meta-regression analysis. Results: Eighteen eligible RCTs, including 15,309 patients and four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin and ipragliflozin) were evaluated. In patients without chronic kidney disease, each SGLT2 inhibitor significantly increased serum magnesium levels compared with placebo (canagliflozin: WMD 0.06 mmol/l for 100 mg and 0.09 mmol/l for 300 mg; dapagliflozin: WMD 0.1 mmol/l for 10 mg; empagliflozin: WMD 0.04 mmol/l for 10 mg and 0.07 mmol/l for 25 mg; and ipragliflozin: WMD 0.05 mmol/l for 50 mg). Canagliflozin increased serum magnesium in a linear dose-dependent manner (p = 0.10). Serum phosphate was significantly increased by dapagliflozin. Serum sodium appeared to significantly differ by SGLT2 inhibitor type. No significant changes in serum calcium and potassium were observed. Findings were robust after including trials involving patients with chronic kidney disease. Conclusions/interpretation: SGLT2 inhibitors marginally increased serum magnesium levels in type 2 diabetes patients indicating a drug class effect. Further investigations are required to examine the clinical significance of elevated magnesium levels in individuals with type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)2546-2551
Number of pages6
JournalDiabetologia
Volume59
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Magnesium
Type 2 Diabetes Mellitus
Meta-Analysis
Randomized Controlled Trials
Serum
Chronic Renal Insufficiency
Electrolytes
Placebos
PubMed
Potassium
Sodium
Phosphates
Regression Analysis
Calcium
Pharmaceutical Preparations
Canagliflozin
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol

Keywords

  • Meta-analysis
  • Serum electrolytes
  • Serum magnesium
  • SGLT2 inhibitors
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients : a meta-analysis of randomised controlled trials. / Tang, Huilin; Zhang, Xi; Zhang, Jingjing; Li, Yufeng; Del Gobbo, Liana C.; Zhai, Suodi; Song, Yiqing.

In: Diabetologia, Vol. 59, No. 12, 01.12.2016, p. 2546-2551.

Research output: Contribution to journalArticle

Tang, Huilin ; Zhang, Xi ; Zhang, Jingjing ; Li, Yufeng ; Del Gobbo, Liana C. ; Zhai, Suodi ; Song, Yiqing. / Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients : a meta-analysis of randomised controlled trials. In: Diabetologia. 2016 ; Vol. 59, No. 12. pp. 2546-2551.
@article{bc0947b6adfe4a8595fc43cc3ee08a5d,
title = "Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials",
abstract = "Aims/hypothesis: By analysing available evidence from randomised controlled trials (RCTs), we aimed to examine whether and to what extent sodium–glucose cotransporter 2 (SGLT2) inhibitors affect serum electrolyte levels in type 2 diabetes patients. Methods: We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov up to 24 May 2016 for published RCTs of SGLT2 inhibitors that reported changes in serum electrolyte levels. Weighted mean differences (WMD) between each SGLT2 inhibitor and placebo were calculated using a random-effects model. Dose-dependent relationships for each SGLT2 inhibitor were evaluated using meta-regression analysis. Results: Eighteen eligible RCTs, including 15,309 patients and four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin and ipragliflozin) were evaluated. In patients without chronic kidney disease, each SGLT2 inhibitor significantly increased serum magnesium levels compared with placebo (canagliflozin: WMD 0.06 mmol/l for 100 mg and 0.09 mmol/l for 300 mg; dapagliflozin: WMD 0.1 mmol/l for 10 mg; empagliflozin: WMD 0.04 mmol/l for 10 mg and 0.07 mmol/l for 25 mg; and ipragliflozin: WMD 0.05 mmol/l for 50 mg). Canagliflozin increased serum magnesium in a linear dose-dependent manner (p = 0.10). Serum phosphate was significantly increased by dapagliflozin. Serum sodium appeared to significantly differ by SGLT2 inhibitor type. No significant changes in serum calcium and potassium were observed. Findings were robust after including trials involving patients with chronic kidney disease. Conclusions/interpretation: SGLT2 inhibitors marginally increased serum magnesium levels in type 2 diabetes patients indicating a drug class effect. Further investigations are required to examine the clinical significance of elevated magnesium levels in individuals with type 2 diabetes.",
keywords = "Meta-analysis, Serum electrolytes, Serum magnesium, SGLT2 inhibitors, Type 2 diabetes",
author = "Huilin Tang and Xi Zhang and Jingjing Zhang and Yufeng Li and {Del Gobbo}, {Liana C.} and Suodi Zhai and Yiqing Song",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s00125-016-4101-6",
language = "English (US)",
volume = "59",
pages = "2546--2551",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients

T2 - a meta-analysis of randomised controlled trials

AU - Tang, Huilin

AU - Zhang, Xi

AU - Zhang, Jingjing

AU - Li, Yufeng

AU - Del Gobbo, Liana C.

AU - Zhai, Suodi

AU - Song, Yiqing

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Aims/hypothesis: By analysing available evidence from randomised controlled trials (RCTs), we aimed to examine whether and to what extent sodium–glucose cotransporter 2 (SGLT2) inhibitors affect serum electrolyte levels in type 2 diabetes patients. Methods: We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov up to 24 May 2016 for published RCTs of SGLT2 inhibitors that reported changes in serum electrolyte levels. Weighted mean differences (WMD) between each SGLT2 inhibitor and placebo were calculated using a random-effects model. Dose-dependent relationships for each SGLT2 inhibitor were evaluated using meta-regression analysis. Results: Eighteen eligible RCTs, including 15,309 patients and four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin and ipragliflozin) were evaluated. In patients without chronic kidney disease, each SGLT2 inhibitor significantly increased serum magnesium levels compared with placebo (canagliflozin: WMD 0.06 mmol/l for 100 mg and 0.09 mmol/l for 300 mg; dapagliflozin: WMD 0.1 mmol/l for 10 mg; empagliflozin: WMD 0.04 mmol/l for 10 mg and 0.07 mmol/l for 25 mg; and ipragliflozin: WMD 0.05 mmol/l for 50 mg). Canagliflozin increased serum magnesium in a linear dose-dependent manner (p = 0.10). Serum phosphate was significantly increased by dapagliflozin. Serum sodium appeared to significantly differ by SGLT2 inhibitor type. No significant changes in serum calcium and potassium were observed. Findings were robust after including trials involving patients with chronic kidney disease. Conclusions/interpretation: SGLT2 inhibitors marginally increased serum magnesium levels in type 2 diabetes patients indicating a drug class effect. Further investigations are required to examine the clinical significance of elevated magnesium levels in individuals with type 2 diabetes.

AB - Aims/hypothesis: By analysing available evidence from randomised controlled trials (RCTs), we aimed to examine whether and to what extent sodium–glucose cotransporter 2 (SGLT2) inhibitors affect serum electrolyte levels in type 2 diabetes patients. Methods: We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov up to 24 May 2016 for published RCTs of SGLT2 inhibitors that reported changes in serum electrolyte levels. Weighted mean differences (WMD) between each SGLT2 inhibitor and placebo were calculated using a random-effects model. Dose-dependent relationships for each SGLT2 inhibitor were evaluated using meta-regression analysis. Results: Eighteen eligible RCTs, including 15,309 patients and four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin and ipragliflozin) were evaluated. In patients without chronic kidney disease, each SGLT2 inhibitor significantly increased serum magnesium levels compared with placebo (canagliflozin: WMD 0.06 mmol/l for 100 mg and 0.09 mmol/l for 300 mg; dapagliflozin: WMD 0.1 mmol/l for 10 mg; empagliflozin: WMD 0.04 mmol/l for 10 mg and 0.07 mmol/l for 25 mg; and ipragliflozin: WMD 0.05 mmol/l for 50 mg). Canagliflozin increased serum magnesium in a linear dose-dependent manner (p = 0.10). Serum phosphate was significantly increased by dapagliflozin. Serum sodium appeared to significantly differ by SGLT2 inhibitor type. No significant changes in serum calcium and potassium were observed. Findings were robust after including trials involving patients with chronic kidney disease. Conclusions/interpretation: SGLT2 inhibitors marginally increased serum magnesium levels in type 2 diabetes patients indicating a drug class effect. Further investigations are required to examine the clinical significance of elevated magnesium levels in individuals with type 2 diabetes.

KW - Meta-analysis

KW - Serum electrolytes

KW - Serum magnesium

KW - SGLT2 inhibitors

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84988410173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988410173&partnerID=8YFLogxK

U2 - 10.1007/s00125-016-4101-6

DO - 10.1007/s00125-016-4101-6

M3 - Article

VL - 59

SP - 2546

EP - 2551

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 12

ER -